InvestSMART

Emyria Limited (ASX: EMD) - Announcements

Current share price for EMD : $0.041 0.001 (2.50%)+

ASX company news and announcements for Emyria Limited (EMD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Emyria Limited (EMD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Emyria Limited (EMD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Emyria Limited (EMD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$33 Euroz Hartleys 2025 Healthcare Forum Presentation 4 Feb 2025 9:31AM $0.035 $0.041 risen by 17.14%
$33 Emyria Reports Promising 3-Month PTSD Treatment Results 4 Feb 2025 9:25AM $0.035 $0.041 risen by 17.14%
$33 December 2024 Quarterly Activities Report and Appendix 4C 31 Jan 2025 12:15PM $0.034 $0.041 risen by 20.59%
$33 Leadership Updates 22 Jan 2025 9:20AM $0.032 $0.041 risen by 28.13%
$33 Section 708A(5)(e) Notice 12 Dec 2024 12:53PM $0.037 $0.041 risen by 10.81%
$33 Application for quotation of securities - EMD 12 Dec 2024 12:49PM $0.037 $0.041 risen by 10.81%
$33 Proposed issue of securities - EMD 27 Nov 2024 10:09AM $0.039 $0.041 risen by 5.13%
$33 Emyria Secures $2.525M in Strongly Supported Placement 27 Nov 2024 10:08AM $0.039 $0.041 risen by 5.13%
$33 Investor Update - November 2024 25 Nov 2024 9:58AM $0.039 $0.041 risen by 5.13%
$33 Trading Halt 25 Nov 2024 9:40AM $0.039 $0.041 risen by 5.13%
$33 Notification of cessation of securities - EMD 15 Nov 2024 6:32PM $0.034 $0.041 risen by 20.59%
$33 Response to ASX Price Query 12 Nov 2024 3:19PM $0.037 $0.041 risen by 10.81%
$33 Results of Annual General Meeting 12 Nov 2024 2:40PM $0.037 $0.041 risen by 10.81%
$33 Proposed issue of securities - EMD 31 Oct 2024 10:44AM $0.031 $0.041 risen by 34.43%
$33 Emyria & UWA Partner to License Novel Serotonin Therapies 31 Oct 2024 9:58AM $0.030 $0.041 risen by 36.67%
$33 September 2024 Quarterly Activities Report and Appendix 4C 30 Oct 2024 10:38AM $0.035 $0.041 risen by 17.14%
$33 Emyria Gains Ethics Endorsement for Psilocybin Program 28 Oct 2024 10:00AM $0.032 $0.041 risen by 28.13%
$33 Letter to Shareholders - Notice of Annual General Meeting 11 Oct 2024 3:53PM $0.030 $0.041 risen by 36.67%
$33 Notice of Annual General Meeting/Proxy Form 11 Oct 2024 3:52PM $0.030 $0.041 risen by 36.67%
$33 Appendix 4G and Corporate Governance Statement 11 Oct 2024 3:50PM $0.030 $0.041 risen by 36.67%
$33 Annual Report 11 Oct 2024 3:50PM $0.030 $0.041 risen by 36.67%
$33 Change of Director's Interest Notice x 2 23 Sep 2024 12:38PM $0.037 $0.041 risen by 10.81%
$33 Section 708A(5)(e) Notice 20 Sep 2024 5:26PM $0.037 $0.041 risen by 10.81%
$33 Notification regarding unquoted securities - EMD 20 Sep 2024 5:19PM $0.037 $0.041 risen by 10.81%
$33 Application for quotation of securities - EMD 20 Sep 2024 5:15PM $0.037 $0.041 risen by 10.81%

151 - 175 of 573 results

Page 7 of 23

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.